{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T08:18:05Z","timestamp":1790497085449,"version":"4.1.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2012,9,19]],"date-time":"2012-09-19T00:00:00Z","timestamp":1348012800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1007\/s11910-012-0313-4","type":"journal-article","created":{"date-parts":[[2012,9,18]],"date-time":"2012-09-18T18:26:54Z","timestamp":1347992814000},"page":"680-686","source":"Crossref","is-referenced-by-count":37,"title":["Update on Progressive Multifocal Leukoencephalopathy"],"prefix":"10.1007","volume":"12","author":[{"given":"Israel","family":"Steiner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph R.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,9,19]]},"reference":[{"key":"313_CR1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/brain\/81.1.93","volume":"81","author":"KE Astrom","year":"1958","unstructured":"Astrom KE, Mancall EL, Richardson Jr EP. Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease. Brain. 1958;81:93\u2013111.","journal-title":"Brain"},{"key":"313_CR2","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S0140-6736(71)91777-6","volume":"1","author":"BL Padgett","year":"1971","unstructured":"Padgett BL, et al. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet. 1971;1:1257\u201360.","journal-title":"Lancet"},{"key":"313_CR3","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1056\/NEJM197202242860801","volume":"286","author":"LP Weiner","year":"1972","unstructured":"Weiner LP, et al. Isolation of virus related to SV40 from patients with progressive multifocal leukoencephalopathy. N Engl J Med. 1972;286:385\u201390.","journal-title":"N Engl J Med"},{"key":"313_CR4","first-page":"342","volume":"50","author":"G Stoner","year":"1991","unstructured":"Stoner G, Ryschkewitsch C. Evidence of JC virus in two progressive multifocal leukoencephalopathy (PML) brains previously reported to be infected with SC40. J Neuropathol Exp Neurol. 1991;50:342.","journal-title":"J Neuropathol Exp Neurol"},{"key":"313_CR5","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ana.22128","volume":"68","author":"L Gorelik","year":"2010","unstructured":"\u2022 Gorelik L, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol. 2010;68:295\u2013303. A study from a leading group in the field that deals with reducing the risk of PML in patients about to receive immuno-suppressive therapies.","journal-title":"Ann Neurol"},{"key":"313_CR6","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1099\/vir.0.18842-0","volume":"84","author":"A Stolt","year":"2003","unstructured":"Stolt A, et al. Seroepidemiology of the human polyomaviruses. J Gen Virol. 2003;84:1499\u2013504.","journal-title":"J Gen Virol"},{"key":"313_CR7","first-page":"99","volume-title":"Polyomaviruses and human neurological disease","author":"D Walker","year":"1983","unstructured":"Walker D, Padgett B. The epidemiology of human polyomaviruses. In: Sever J, Madden D, editors. Polyomaviruses and human neurological disease. New York: Alan R. Liss, Inc; 1983. p. 99\u2013106."},{"key":"313_CR8","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/13550280152537210","volume":"7","author":"S Bofill-Mas","year":"2001","unstructured":"Bofill-Mas S, Girones R. Excretion and transmission of JCV in human populations. J Neuroviro. 2001;7:345\u20139.","journal-title":"J Neuroviro"},{"key":"313_CR9","doi-asserted-by":"crossref","unstructured":"Zaheer F, Berger JR. Treatment related progressive multifocal leukoencephalopathy: current understanding and future steps. Ther Advances Drug Safety. 2012 (in press).","DOI":"10.1177\/2042098612453849"},{"key":"313_CR10","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0733-8619(18)31105-8","volume":"2","author":"BR Brooks","year":"1984","unstructured":"Brooks BR, Walker DL. Progressive multifocal leukoencephalopathy. Neurol Clin. 1984;2:299\u2013313.","journal-title":"Neurol Clin"},{"key":"313_CR11","doi-asserted-by":"crossref","first-page":"78","DOI":"10.7326\/0003-4819-107-1-78","volume":"107","author":"JR Berger","year":"1987","unstructured":"Berger JR, et al. Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. A review of the literature with a report of sixteen cases. Ann Intern Med. 1987;107:78\u201387.","journal-title":"Ann Intern Med"},{"key":"313_CR12","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/0046-8177(91)90293-X","volume":"22","author":"K Kure","year":"1991","unstructured":"Kure K, et al. Human immunodeficiency virus-1 infection of the nervous system: an autopsy study of 268 adult, pediatric, and fetal brains. Hum Pathol. 1991;22:700\u201310.","journal-title":"Hum Pathol"},{"key":"313_CR13","doi-asserted-by":"crossref","first-page":"869","DOI":"10.2165\/00023210-200317120-00002","volume":"17","author":"J Collazos","year":"2003","unstructured":"Collazos J. Opportunistic infections of the CNS in patients with AIDS: diagnosis and management. CNS Drugs. 2003;17:869\u201387.","journal-title":"CNS Drugs"},{"key":"313_CR14","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899\u2013910.","journal-title":"N Engl J Med"},{"key":"313_CR15","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1056\/NEJMe058122","volume":"353","author":"JR Berger","year":"2005","unstructured":"Berger JR, Koralnik IJ. Progressive multifocal leukoencephalopathy and natalizumab\u2013unforeseen consequences. N Engl J Med. 2005;353:414\u20136.","journal-title":"N Engl J Med"},{"key":"313_CR16","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMoa051782","volume":"353","author":"BK Kleinschmidt-DeMasters","year":"2005","unstructured":"Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med. 2005;353:369\u201374.","journal-title":"N Engl J Med"},{"key":"313_CR17","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1056\/NEJMoa051847","volume":"353","author":"A Langer-Gould","year":"2005","unstructured":"Langer-Gould A, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005;353:375\u201381.","journal-title":"N Engl J Med"},{"key":"313_CR18","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa051586","volume":"353","author":"G Assche Van","year":"2005","unstructured":"Van Assche G, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med. 2005;353:362\u20138.","journal-title":"N Engl J Med"},{"key":"313_CR19","unstructured":"BiogenIdec. PML incidence in patients receiving TYSABRI. 2012 [cited July 2, 2012]; Available at: https:\/\/medinfo.biogenidec.com\/medinfo\/secure\/pmlresource.do?resource=TYSABRIPMLSafetyUpdate . Accessed 10 July 2012."},{"key":"313_CR20","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","volume":"366","author":"G Bloomgren","year":"2012","unstructured":"\u2022 Bloomgren G, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Eng J Med. 2012;366:1870\u201380. A recent study that assesses who is at risk to develop PML under natalizumab therapy.","journal-title":"N Eng J Med"},{"key":"313_CR21","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1001\/jama.290.23.3073","volume":"290","author":"KB Gordon","year":"2003","unstructured":"Gordon KB, et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA. 2003;290:3073\u201380.","journal-title":"JAMA"},{"key":"313_CR22","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1056\/NEJMoa030002","volume":"349","author":"M Lebwohl","year":"2003","unstructured":"Lebwohl M, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med. 2003;349:2004\u201313.","journal-title":"N Engl J Med"},{"key":"313_CR23","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","volume":"113","author":"KR Carson","year":"2009","unstructured":"Carson KR, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on adverse drug events and reports project. Blood. 2009;113:4834\u201340.","journal-title":"Blood"},{"key":"313_CR24","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/ajh.20492","volume":"80","author":"J Garcia-Suarez","year":"2005","unstructured":"Garcia-Suarez J, et al. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies. Am J Hematol. 2005;80:271\u201381.","journal-title":"Am J Hematol"},{"issue":"Suppl 1","key":"313_CR25","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1080\/13550280390195261","volume":"9","author":"JR Berger","year":"2003","unstructured":"Berger JR. Progressive multifocal leukoencephalopathy in acquired immunodeficiency syndrome: explaining the high incidence and disproportionate frequency of the illness relative to other immunosuppressive conditions. J Neuroviro. 2003;9 Suppl 1:38\u201341.","journal-title":"J Neuroviro"},{"key":"313_CR26","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3109\/13550289909021994","volume":"5","author":"R Caldarelli-Stefano","year":"1999","unstructured":"Caldarelli-Stefano R, et al. Detection and typing of JC virus in autopsy brains and extraneural organs of AIDS patients and non-immunocompromised individuals. J Neuroviro. 1999;5:125\u201333.","journal-title":"J Neuroviro"},{"key":"313_CR27","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1080\/13550280152537102","volume":"7","author":"PN Jensen","year":"2001","unstructured":"Jensen PN, Major EO. A classification scheme for human polyomavirus JCV variants based on the nucleotide sequence of the noncoding regulatory region. J Neuroviro. 2001;7:280\u20137.","journal-title":"J Neuroviro"},{"key":"313_CR28","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/jnr.490270405","volume":"27","author":"EO Major","year":"1990","unstructured":"Major EO, et al. Glial cells of the human developing brain and B cells of the immune system share a common DNA binding factor for recognition of the regulatory sequences of the human polyomavirus, JCV. J Neurosci Res. 1990;27:461\u201371.","journal-title":"J Neurosci Res"},{"key":"313_CR29","doi-asserted-by":"crossref","first-page":"7004","DOI":"10.1128\/JVI.70.10.7004-7012.1996","volume":"70","author":"MC Monaco","year":"1996","unstructured":"Monaco MC, et al. JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency. J Virol. 1996;70:7004\u201312.","journal-title":"J Virol"},{"key":"313_CR30","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/13550280802348222","volume":"14","author":"SA Houff","year":"2008","unstructured":"Houff SA, Berger JR. The bone marrow, B cells, and JC virus. J Neuroviro. 2008;14:341\u20133.","journal-title":"J Neuroviro"},{"key":"313_CR31","doi-asserted-by":"crossref","first-page":"e1000368","DOI":"10.1371\/journal.pgen.1000368","volume":"5","author":"SR Sunyaev","year":"2009","unstructured":"Sunyaev SR, et al. Adaptive mutations in the JC virus protein capsid are associated with progressive multifocal leukoencephalopathy (PML). PLoS Genet. 2009;5:e1000368.","journal-title":"PLoS Genet"},{"key":"313_CR32","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/WCO.0b013e328346be6f","volume":"24","author":"I Steiner","year":"2011","unstructured":"Steiner I. Herpes simplex virus encephalitis: new infection or reactivation? Curr Opin Neurol. 2011;24:268\u201374.","journal-title":"Curr Opin Neurol"},{"key":"313_CR33","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/ana.1004","volume":"49","author":"F Weber","year":"2001","unstructured":"Weber F, et al. Cellular and humoral immune response in progressive multifocal leukoencephalopathy. Ann Neurol. 2001;49:636\u201342.","journal-title":"Ann Neurol"},{"key":"313_CR34","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/00002030-199208000-00012","volume":"6","author":"JR Berger","year":"1992","unstructured":"Berger JR, et al. Progressive multifocal leukoencephalopathy in HIV-1-infected children. AIDS. 1992;6:837\u201341.","journal-title":"AIDS"},{"key":"313_CR35","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1080\/13550280390241188","volume":"9","author":"CG Fedele","year":"2003","unstructured":"Fedele CG, et al. Identical rearranged forms of JC polyomavirus transcriptional control region in plasma and cerebrospinal fluid of acquired immunodeficiency syndrome patients with progressive multifocal leukoencephalopathy. J Neuroviro. 2003;9:551\u20138.","journal-title":"J Neuroviro"},{"key":"313_CR36","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1001\/archneur.1994.00540160128016","volume":"51","author":"DA Katz","year":"1994","unstructured":"Katz DA, et al. Progressive multifocal leukoencephalopathy complicating Wiskott-Aldrich syndrome. Report of a case and review of the literature of progressive multifocal leukoencephalopathy with other inherited immunodeficiency states. Arch Neurol. 1994;51:422\u20136.","journal-title":"Arch Neurol"},{"key":"313_CR37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jmv.2103","volume":"66","author":"L Andreoletti","year":"2002","unstructured":"Andreoletti L, et al. Semiquantitative detection of JCV-DNA in peripheral blood leukocytes from HIV-1-infected patients with or without progressive multifocal leukoencephalopathy. J Med Virol. 2002;66:1\u20137.","journal-title":"J Med Virol"},{"issue":"Suppl 3","key":"313_CR38","first-page":"211","volume":"42","author":"C Tornatore","year":"1992","unstructured":"Tornatore C, et al. Detection of JC viral genome in the lymphocytes of non-PML HIV positive patients: association with B cell lymphopenia. Neurology. 1992;42 Suppl 3:211.","journal-title":"Neurology"},{"key":"313_CR39","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1086\/374048","volume":"36","author":"J Berenguer","year":"2003","unstructured":"Berenguer J, et al. Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy. Clin Infect Dis. 2003;36:1047\u201352.","journal-title":"Clin Infect Dis"},{"key":"313_CR40","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1080\/13550280152537247","volume":"7","author":"P Cinque","year":"2001","unstructured":"Cinque P, et al. The good and evil of HAART in HIV-related progressive multifocal leukoencephalopathy. J Neuroviro. 2001;7:358\u201363.","journal-title":"J Neuroviro"},{"key":"313_CR41","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1128\/JVI.75.7.3483-3487.2001","volume":"75","author":"IJ Koralnik","year":"2001","unstructured":"Koralnik IJ, Du Pasquier RA, Letvin NL. JC virus-specific cytotoxic T lymphocytes in individuals with progressive multifocal leukoencephalopathy. J Virol. 2001;75:3483\u20137.","journal-title":"J Virol"},{"key":"313_CR42","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1212\/01.wnl.0000327671.91357.96","volume":"71","author":"M Krumbholz","year":"2008","unstructured":"Krumbholz M, et al. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology. 2008;71:1350\u20134.","journal-title":"Neurology"},{"key":"313_CR43","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1080\/13550280152537175","volume":"7","author":"RA Pasquier Du","year":"2001","unstructured":"Du Pasquier RA, et al. JCV-specific cellular immune response correlates with a favorable clinical outcome in HIV-infected individuals with progressive multifocal leukoencephalopathy. J Neuroviro. 2001;7:318\u201322.","journal-title":"J Neuroviro"},{"key":"313_CR44","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1093\/brain\/awh215","volume":"127","author":"RA Pasquier Du","year":"2004","unstructured":"Du Pasquier RA, et al. A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain. 2004;127:1970\u20138.","journal-title":"Brain"},{"key":"313_CR45","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.virol.2008.10.046","volume":"383","author":"A Marzocchetti","year":"2009","unstructured":"Marzocchetti A, et al. Efficient in vitro expansion of JC virus-specific CD8(+) T-cell responses by JCV peptide-stimulated dendritic cells from patients with progressive multifocal leukoencephalopathy. Virology. 2009;383:173\u20137.","journal-title":"Virology"},{"key":"313_CR46","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1001\/archneur.65.12.noc80051","volume":"65","author":"M Pilar Martin del","year":"2008","unstructured":"del Pilar Martin M, et al. Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. Arch Neurol. 2008;65:1596\u2013603.","journal-title":"Arch Neurol"},{"key":"313_CR47","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1159\/000077660","volume":"208","author":"D Jullien","year":"2004","unstructured":"Jullien D, et al. T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action. Dermatology. 2004;208:297\u2013306.","journal-title":"Dermatology"},{"key":"313_CR48","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1358\/dot.2004.40.11.872578","volume":"40","author":"KA Papp","year":"2004","unstructured":"Papp KA. Efalizumab: advancing psoriasis management with a novel, targeted T-cell modulator. Drugs Today (Barc). 2004;40:889\u201399.","journal-title":"Drugs Today (Barc)"},{"key":"313_CR49","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1177\/039463200802100224","volume":"21","author":"F Capsoni","year":"2008","unstructured":"Capsoni F, et al. Effect of Efalizumab on neutrophil and monocyte functions in patients with psoriasis. Int J Immunopathol Pharmacol. 2008;21:437\u201345.","journal-title":"Int J Immunopathol Pharmacol"},{"key":"313_CR50","doi-asserted-by":"crossref","first-page":"19057","DOI":"10.1073\/pnas.0509736102","volume":"102","author":"MA Lowes","year":"2005","unstructured":"Lowes MA, et al. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci U S A. 2005;102:19057\u201362.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"313_CR51","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1212\/WNL.0b013e3182478d4b","volume":"78","author":"N Schwab","year":"2012","unstructured":"\u2022 Schwab N, et al. Fatal PML associated with efalizumab therapy: insights into integrin alphaLbeta2 in JC virus control. Neurology. 2012;78:458\u201367. discussion 465. A recent observation on the possible pathogenesis of PML under monoclonal antibody therapy.","journal-title":"Neurology"},{"key":"313_CR52","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jneuroim.2006.06.029","volume":"180","author":"AH Cross","year":"2006","unstructured":"Cross AH, et al. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol. 2006;180:63\u201370.","journal-title":"J Neuroimmunol"},{"key":"313_CR53","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s11481-010-9203-1","volume":"5","author":"LJ Marshall","year":"2010","unstructured":"Marshall LJ, Major EO. Molecular regulation of JC virus tropism: insights into potential therapeutic targets for progressive multifocal leukoencephalopathy. J Neuroimmune Pharmacol. 2010;5:404\u201317.","journal-title":"J Neuroimmune Pharmacol"},{"key":"313_CR54","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/ana.410310426","volume":"31","author":"C Tornatore","year":"1992","unstructured":"Tornatore C, et al. Detection of JC virus DNA in peripheral lymphocytes from patients with and without progressive multifocal leukoencephalopathy. Ann Neurol. 1992;31:454\u201362.","journal-title":"Ann Neurol"},{"issue":"Suppl 2","key":"313_CR55","first-page":"83","volume":"11","author":"JR Berger","year":"2005","unstructured":"Berger JR, et al. Are saliva and oropharyngeal secretions a source of JCV infection? J Neuroviro. 2005;11 Suppl 2:83.","journal-title":"J Neuroviro"},{"key":"313_CR56","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/infdis\/jiq097","volume":"203","author":"MK White","year":"2011","unstructured":"White MK, Khalili K. Pathogenesis of progressive multifocal leukoencephalopathy\u2013revisited. J Infect Dis. 2011;203:578\u201386.","journal-title":"J Infect Dis"},{"key":"313_CR57","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/PAT.0b013e3283463558","volume":"43","author":"J Bayliss","year":"2011","unstructured":"Bayliss J, et al. Immunosuppression increases latent infection of brain by JC polyomavirus. Pathology. 2011;43:362\u20137.","journal-title":"Pathology"},{"key":"313_CR58","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/NEN.0b013e318181b4da","volume":"67","author":"EJ Rushing","year":"2008","unstructured":"Rushing EJ, et al. Immune reconstitution inflammatory syndrome of the brain: case illustrations of a challenging entity. J Neuropathol Exp Neurol. 2008;67:819\u201327.","journal-title":"J Neuropathol Exp Neurol"},{"key":"313_CR59","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/QAI.0b013e3181594c8c","volume":"46","author":"YC Manabe","year":"2007","unstructured":"Manabe YC, et al. Immune reconstitution inflammatory syndrome: risk factors and treatment implications. J Acquir Immune Defic Syndr. 2007;46:456\u201362.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"313_CR60","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/01.aids.0000161769.06158.8a","volume":"19","author":"SA Shelburne","year":"2005","unstructured":"Shelburne SA, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS. 2005;19:399\u2013406.","journal-title":"AIDS"},{"key":"313_CR61","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1097\/00002030-200210180-00009","volume":"16","author":"P Price","year":"2002","unstructured":"Price P, et al. Polymorphisms in cytokine genes define subpopulations of HIV-1 patients who experienced immune restoration diseases. AIDS. 2002;16:2043\u20137.","journal-title":"AIDS"},{"key":"313_CR62","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/QAI.0b013e31817bec64","volume":"49","author":"V Falco","year":"2008","unstructured":"Falco V, et al. Influence of HAART on the clinical course of HIV-1-infected patients with progressive multifocal leukoencephalopathy: results of an observational multicenter study. J Acquir Immune Defic Syndr. 2008;49:26\u201331.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"313_CR63","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S1474-4422(10)70028-4","volume":"9","author":"DB Clifford","year":"2010","unstructured":"Clifford DB, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 2010;9:438\u201346.","journal-title":"Lancet Neurol"},{"key":"313_CR64","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1001\/archneurol.2010.257","volume":"68","author":"A Miravalle","year":"2010","unstructured":"Miravalle A, Jensen R, Kinkel RP. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol. 2010;68:186\u201391.","journal-title":"Arch Neurol"},{"key":"313_CR65","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/WCO.0b013e328346be57","volume":"24","author":"T Johnson","year":"2011","unstructured":"\u2022 Johnson T, Nath A. Immune reconstitution inflammatory syndrome and the central nervous system. Curr Opin Neurol. 2011;24:284\u201390. A recent comprahensive review on IRIS.","journal-title":"Curr Opin Neurol"},{"key":"313_CR66","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1586\/eri.11.21","volume":"9","author":"SD Lawn","year":"2011","unstructured":"Lawn SD, Meintjes G. Pathogenesis and prevention of immune reconstitution disease during antiretroviral therapy. Expert Rev Anti Infect Ther. 2011;9:415\u201330.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"313_CR67","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(10)70040-5","volume":"9","author":"CS Tan","year":"2010","unstructured":"Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol. 2010;9:425\u201337.","journal-title":"Lancet Neurol"},{"key":"313_CR68","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1097\/QAD.0b013e32833dfc68","volume":"24","author":"G Meintjes","year":"2010","unstructured":"Meintjes G, et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS. 2010;24:2381\u201390.","journal-title":"AIDS"},{"key":"313_CR69","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1055\/s-0030-1266063","volume":"38","author":"HP Hartung","year":"2011","unstructured":"Hartung HP. et al [Therapie der Multiplen Sklerose mit monokonalen Antikorpen: aktualisierte Empfelungen im Rahmen eines Expert meetings]. Actuelle Neurol. 2011;38:2\u201311.","journal-title":"Actuelle Neurol"},{"key":"313_CR70","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1212\/01.wnl.0000343735.44983.5e","volume":"72","author":"JR Berger","year":"2009","unstructured":"Berger JR. Steroids for PML-IRIS: a double-edged sword? Neurology. 2009;72:1454\u20135.","journal-title":"Neurology"},{"issue":"Suppl 2","key":"313_CR71","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.3949\/ccjm.78.s2.03","volume":"78","author":"JR Berger","year":"2011","unstructured":"Berger JR. The clinical features of PML. Cleve Clin J Med. 2011;78 Suppl 2:S8\u201312.","journal-title":"Cleve Clin J Med"},{"key":"313_CR72","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1148\/radiology.187.1.8451420","volume":"187","author":"ML Whiteman","year":"1993","unstructured":"Whiteman ML, et al. Progressive multifocal leukoencephalopathy in 47 HIV-seropositive patients: neuroimaging with clinical and pathologic correlation. Radiology. 1993;187:233\u201340.","journal-title":"Radiology"},{"key":"313_CR73","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3109\/13550289809113482","volume":"4","author":"JR Berger","year":"1998","unstructured":"Berger JR, et al. Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neuroviro. 1998;4:59\u201368.","journal-title":"J Neuroviro"},{"key":"313_CR74","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1097\/QAD.0b013e32830a5043","volume":"22","author":"A Luca De","year":"2008","unstructured":"De Luca A, et al. Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis. AIDS. 2008;22:1759\u201367.","journal-title":"AIDS"},{"key":"313_CR75","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1097\/00002030-200209060-00012","volume":"16","author":"CM Marra","year":"2002","unstructured":"Marra CM, et al. A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. AIDS. 2002;16:1791\u20137.","journal-title":"AIDS"},{"key":"313_CR76","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1086\/515153","volume":"28","author":"A Luca De","year":"1999","unstructured":"De Luca A, et al. Clinical and virological monitoring during treatment with intrathecal cytarabine in patients with AIDS-associated progressive multifocal leukoencephalopathy. Clin Infect Dis. 1999;28:624\u20138.","journal-title":"Clin Infect Dis"},{"key":"313_CR77","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJM199805073381903","volume":"338","author":"CD Hall","year":"1998","unstructured":"Hall CD, et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team [see comments]. N Engl J Med. 1998;338:1345\u201351.","journal-title":"N Engl J Med"},{"key":"313_CR78","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1126\/science.1103492","volume":"306","author":"GF Elphick","year":"2004","unstructured":"Elphick GF, et al. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science. 2004;306:1380\u20133.","journal-title":"Science"},{"key":"313_CR79","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1212\/WNL.0b013e3181c0d4a1","volume":"73","author":"A Marzocchetti","year":"2009","unstructured":"Marzocchetti A, et al. Determinants of survival in progressive multifocal leukoencephalopathy. Neurology. 2009;73:1551\u20138.","journal-title":"Neurology"},{"key":"313_CR80","doi-asserted-by":"crossref","unstructured":"Brickelmaier M, et al. Identification and characterization of mefloquine efficacy against Jc virus in vitro. Antimicrob Agents Chemother. 2009.","DOI":"10.1128\/AAC.01614-08"},{"issue":"10","key":"313_CR81","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.2169\/internalmedicine.51.6810","volume":"51","author":"M Beppu","year":"2012","unstructured":"Beppu M, et al. Mefloquine improved progressive multifocal leukoencephalopathy in a patient with systemic lupus erythematosus. Intern Med. 2012;51(10):1245\u20137.","journal-title":"Intern Med"},{"issue":"6","key":"313_CR82","doi-asserted-by":"crossref","first-page":"496","DOI":"10.2146\/ajhp110392","volume":"69","author":"RP Moenster","year":"2012","unstructured":"Moenster RP, Jett RA. Mirtazapine and mefloquine therapy for progressive multifocal leukoencephalopathy in a patient infected with human immunodeficiency virus. Am J Health Syst Pharm. 2012;69(6):496\u20138.","journal-title":"Am J Health Syst Pharm"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-012-0313-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11910-012-0313-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-012-0313-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T10:15:19Z","timestamp":1643451319000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11910-012-0313-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,19]]},"references-count":82,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["313"],"URL":"https:\/\/doi.org\/10.1007\/s11910-012-0313-4","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,19]]}}}